Welcome to Idorsia

Our key assets have
the potential to
transform treatment in
the target indications...

Annual Report

Our 2020 report
consists of four
books

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

11 Oct 2021	Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease
29 Jul 2021	Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd
28 Jul 2021	Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today

Event	When
Nine-months 2021 Financial Results reporting*	October 26, 2021
Full-Year 2021 Financial Results reporting*	February 8, 2022
First-Quarter 2022 Financial Results reporting*	April 26, 2022

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:20:06 CET

20.56 CHF

0.00 (0.00 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland